Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX) Share Price

Price 0.24p on 19-12-2025 at 19:30:07
Change 0.00p 0%
Buy 0.25p
Sell 0.23p
Last Trade: Sell 1,429,164.00 at 0.23p
Day's Volume: 7,137,589
Last Close: 0.24p
Open: 0.24p
ISIN: GB00BYW79Y38
Day's Range 0.24p - 0.24p
52wk Range: 0.045p - 0.53p
Market Capitalisation: £5.06m
VWAP: 0.236771p
Shares in Issue: 2.11b

Nuformix (NFX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 1,429,164 0.23p Ordinary
16:18:12 - 19-Dec-25
Buy* 88 0.25p Ordinary
16:11:30 - 19-Dec-25
Buy* 1,392 0.25p Ordinary
16:10:35 - 19-Dec-25
Sell* 339,990 0.232p Ordinary
15:09:03 - 19-Dec-25
Sell* 708 0.23p Ordinary
14:29:34 - 19-Dec-25
Buy* 166,236 0.2496p Ordinary
14:07:12 - 19-Dec-25
Buy* 200,000 0.249p Ordinary
14:06:18 - 19-Dec-25
Sell* 100,000 0.232p Ordinary
13:30:40 - 19-Dec-25
Sell* 30,386 0.23p SI Trade
11:52:12 - 19-Dec-25
Buy* 1,623,859 0.2441p Ordinary
11:51:59 - 19-Dec-25
See more Nuformix trades

Nuformix (NFX) Share Price History

Time period:
to
Date Open High Low Close Volume
19th Dec 2025 (Fri) 0.24 0.24 0.24 0.24 7,137,589
18th Dec 2025 (Thu) 0.25 0.25 0.24 0.24 8,980,050
17th Dec 2025 (Wed) 0.25 0.25 0.24 0.25 8,056,044
16th Dec 2025 (Tue) 0.27 0.27 0.25 0.25 4,757,311
15th Dec 2025 (Mon) 0.265 0.2875 0.265 0.27 22,283,690
12th Dec 2025 (Fri) 0.21 0.285 0.21 0.265 75,998,075
11th Dec 2025 (Thu) 0.236 0.25 0.185 0.21 93,282,477
10th Dec 2025 (Wed) 0.255 0.251 0.25 0.25 5,704,925
9th Dec 2025 (Tue) 0.255 0.255 0.245 0.255 1,233,924
8th Dec 2025 (Mon) 0.255 0.255 0.25 0.255 12,317,113
5th Dec 2025 (Fri) 0.26 0.26 0.255 0.255 17,370,731
4th Dec 2025 (Thu) 0.255 0.245 0.245 0.245 11,007,110
3rd Dec 2025 (Wed) 0.26 0.26 0.255 0.255 24,864,477
2nd Dec 2025 (Tue) 0.26 0.27 0.26 0.26 6,631,830
1st Dec 2025 (Mon) 0.275 0.275 0.255 0.26 4,395,776
28th Nov 2025 (Fri) 0.275 0.275 0.275 0.275 14,416,784
27th Nov 2025 (Thu) 0.28 0.28 0.275 0.275 6,483,347
26th Nov 2025 (Wed) 0.295 0.285 0.28 0.28 15,297,440
25th Nov 2025 (Tue) 0.305 0.31 0.295 0.295 12,530,549
24th Nov 2025 (Mon) 0.31 0.30 0.30 0.30 6,616,717
21st Nov 2025 (Fri) 0.32 0.32 0.30 0.31 26,864,312
20th Nov 2025 (Thu) 0.325 0.33 0.325 0.325 12,158,500
See more Nuformix price history

Nuformix (NFX) Regulatory News

Date Source Headline
28th Nov 2025 3:22 pm RNS Total Voting Rights
12th Nov 2025 7:01 am RNS Update re. US FDA ODD Application
12th Nov 2025 7:00 am RNS Results of Underwritten Open Offer
28th Oct 2025 7:00 am RNS Underwritten Open Offer
10th Oct 2025 7:00 am RNS Change of Auditor
25th Sep 2025 7:00 am RNS-R European Respiratory Society Congress Attendance
11th Aug 2025 7:00 am RNS US FDA ODD Application Submitted for NXP002
30th May 2025 2:24 pm RNS Total Voting Rights
29th May 2025 7:00 am RNS Confirmation of European ODD for NXP002
23rd May 2025 1:08 pm RNS Publication of a Prospectus
See more Nuformix regulatory news

Nuformix (NFX) Share News

IN BRIEF: Nuformix raises GBP228,000 in open offer

12th Nov 2025 16:59

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Raises approximately GBP228,081 through an underwritten open offer at an issue price of 0.2 pence per share. Valid acceptances were received from qualifying shareholders for 465.8 million shares, representing more than four times the 114.0 million shares available. The full amount of 114.0 million shares will be issued in connection with the open offer. Company says applications for open offer shares under the excess application facility will be scaled back on a pro-rata basis. Expects dealings in the new shares to commence in London on Thursday. Read More

TRADING UPDATES: Celsius raises funds; Built Cybernetics acquisition

12th Nov 2025 15:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: Nuformix submits FDA drug designation application for NXP002

11th Aug 2025 12:11

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Read More

Nuformix shares fall despite EU orphan drug status for lead treatment

29th May 2025 18:21

(Alliance News) - Nuformix PLC on Thursday said its lead programme, NXP002, has been granted orphan drug designation by the European Medicines Agency for the treatment of idiopathic pulmonary fibrosis. Read More

Nuformix interim loss widens as focused on advancing assets

2nd May 2025 12:19

(Alliance News) - Nuformix PLC on Friday said it has continued to "advance and exploit" assets in its portfolio, two days after noting a positive opinion from an EU committee for NXP002. Read More

See more Nuformix news
FTSE 100 Latest
Value9,897.42
Change59.65

Login to your account

Forgot Password?

Not Registered